Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year contin
about
Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implicationsThe supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritisThe Effect of Stopping Smoking on Disease Activity in Rheumatoid Arthritis (RA). Data from BARFOT, a Multicenter Study of Early RAEvidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: a systematic review.Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study.Early remission is associated with improved survival in patients with inflammatory polyarthritis: results from the Norfolk Arthritis Register.Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?The value of glucocorticoid co-therapy in different rheumatic diseases--positive and adverse effectsEarly increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritisReduction of long-term disability in inflammatory polyarthritis by early and persistent suppression of joint inflammation: results from the Norfolk Arthritis Register.The importance of assessment and management of morning stiffness in Asian patients with rheumatoid arthritis: Recommendations from an expert panel.Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registryRheumatoid Arthritis: Early diagnosis and treatment outcomes.Serological identification of fast progressors of structural damage with rheumatoid arthritis.Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial.Designing micro- and nano-particles for treating rheumatoid arthritis.Disease control with glucocorticoid therapy in rheumatoid arthritis.Glucocorticoids in rheumatoid arthritis.German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.The intelligent use of systemic glucocorticoids in rheumatoid arthritis.Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis.Glucocorticoid treatment in rheumatoid arthritis.Changes in hand bone mineral density and the association with the level of disease activity in patients with rheumatoid arthritis: bone mineral density measurements in a multicenter randomized clinical trial.Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial.Changes in body composition after 2 years with rheumatoid arthritis.Glucocorticoids, Inflammation and Bone.[Systematic literature research for S1 guidelines on sequential medical treatment of rheumatoid arthritis].
P2860
Q26738960-B8F3AB9A-3A61-4764-93BB-ECA24D876ADDQ28084878-39CE1B08-67B6-4534-B8B7-D70AD96973DFQ30575606-38C79402-7EAC-4FCC-ABC1-B1DB4A9C0DF1Q33535269-5C08A118-EAD1-425C-92E8-5086CEC37421Q33765844-0642ECA6-45C9-4B43-A027-C0C1EA8EE47DQ34092449-FE998BA2-0B77-4659-8789-D0FBEDB4F4ABQ34559803-28016654-4A23-466D-B515-48D93383B426Q34597321-4C6F729F-D78C-4A03-A715-22D1C3B934FCQ34894822-A6B270BE-C334-4369-BF61-B254144A4560Q35144251-BB0B9969-D15B-41FF-A040-710CB01CAE75Q35786849-C8E7A9FA-86BF-4FC3-85A6-FF4A74476021Q36024297-9AFA8800-E337-4A46-AF27-600B2E9A6BD1Q37155766-C755F9A3-3411-4E25-B36C-2B27B62C4259Q37689708-31702BA8-9708-45DC-9B67-15EAC2710E98Q37704498-AAC73077-E4A9-4132-8DB9-86A212D6B06AQ37964579-A8DC01B9-51E0-4415-B12A-A52DDC1876BEQ38017653-992E0DB3-695E-4155-A394-3BB92951B935Q38075503-109E2DD8-949E-4C11-8A3A-C8A576540257Q38128726-95C97421-E10D-495F-8223-9C1BAA2C61F0Q38168952-CA1D4300-3DDC-4061-8454-465DCFA9F24CQ38204350-7CECEF1E-1C0B-40FD-9773-FFF172EC81EDQ38214242-0878BFDF-7B23-4698-80BB-1D1E8C3FF729Q39998140-07DB55A8-8A7B-41ED-BE8D-9A465A3CC9AEQ40588909-80AB6337-5198-4C64-8744-53F310525991Q44174557-CE730A11-209E-439C-AAB1-C1ED00C57913Q50128187-81AA4E2D-6B87-4F1D-8AE2-AA17B54E345BQ52887079-945C3401-EB6D-455F-81A8-6BAE8C18A338
P2860
Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year contin
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Remission achieved after 2 yea ...... 4 years: an open 2-year contin
@en
Remission achieved after 2 yea ...... 4 years: an open 2-year contin
@nl
type
label
Remission achieved after 2 yea ...... 4 years: an open 2-year contin
@en
Remission achieved after 2 yea ...... 4 years: an open 2-year contin
@nl
prefLabel
Remission achieved after 2 yea ...... 4 years: an open 2-year contin
@en
Remission achieved after 2 yea ...... 4 years: an open 2-year contin
@nl
P2093
P356
P1476
Remission achieved after 2 yea ...... 4 years: an open 2-year contin
@en
P2093
B Svensson
BARFOT Study Group
D van der Heijde
I Hafström
K Albertsson
P304
P356
10.1136/ARD.2008.087833
P407
P577
2008-04-17T00:00:00Z